Member Info for Bobbler

WIF: I ofern thinc yor england languish is paw.

HBD, you are correct ref the patent lawyers!

Good afternoon HBD.
A global patent or the facility to file for a global patent does not exist. When filing for a patent, for example in the U.K. you have a window of 18months from the date of the original filing (priority date) to start the process in another country or country’s. A separate application has to be made for each separate territory. And there is no automatic guarantee that it will be granted despite it being granted in the original country. The patent cooperation treaty (PCT), which the majority of countries are signed up to, aims to streamline the process.

In a nutshell a U.K. patent prevents the selling, manufacturing of the protected product/ process in the U.K. but doesn’t stop infringement in any other country.

Mafuta.
You missed off end of that sentence.
“License or partner to a pharmaceutical major”

Suggesting that they’re speaking with the big players???

SCHeckler, it’s an interesting statement. Particularly as they make a point about not having any influence or direct line of comm’s with GSK ref the SRA737 deal. In fact they claim they are speaking regularly with CRT ref STA737.

Yet the statement could easily lead one to the inference that they are party to confidential information that’s not yet in the public domain. Can only assume this has come from CRT??? Who knows.

“We can't divulge anything Gsk haven't put into the public domain”

Groverlad. I assume would agree BP is a pretty solid company? It’s share price is very similar to where it was 5 years ago, and it makes significant profits. Now have a look at the percentage increase in Sareum SP from where it was 5 years ago.

Yes, I would imagine there are a lot of people frustrated at reading the complete toilet deposits yo post. All my own opinion, please do your own research all alternative trash other people research with constant negativity and nothing else.

C79, thanks for the info. Looking at the co-inventors (Julian Northern) it would appear very likely that Onyx scientific are the people manufacturing the capsules for the trials.

"Our Phase I-III small molecule API development and manufacturing services support you through each preclinical research stage. Led by a team of highly skilled chemists, our approach focuses on seamlessly moving APIs from the lab to the plant, offering a smooth and flexible process from quality assurance and GMP manufacture through to analytical method development and stability testing".

https://onyxipca.com/cmc-services/?_gl=1*1yu6wsg*_up*MQ..&gclid=EAIaIQobChMI-aeBr8K--QIVwoFQBh2qOgWEEAAYASAAEgLJF_D_BwE#section-3

Colbaltblue, do you think its a negative that GSK now own SRA 737? do you not feel it has a far better chance of being progressed now that its in the hands of a major? curious to hear how you feel as an investor

Good afternoon SOG,

This is an interested read, published last month.

"Analyses of clinical trial data from 2010 to 2017 show four possible reasons attributed to the 90% clinical failures of drug development: lack of clinical efficacy (40%–50%), unmanageable toxicity (30%), poor drug-like properties (10%–15%), and lack of commercial needs and poor strategic planning (10%)"
https://www.sciencedirect.com/science/article/pii/S2211383522000521#:~:text=Analyses%20of%20clinical%20trial%20data,(10%25)2%2C4.

Regards

Okay Colbaltblue, I appreciate positivity is not your thing. However please take a look at this recent study the author is Shingo Yamaguchi an employee of GlaxoSmithKline K.K., Tokyo, Japan.
Approval success rates of drug candidates based on target, action, modality, application, and their combinations.

"The current success rate of a drug candidate, from the beginning of the clinical trial to receiving marketing approval, is about 10%-20%, and it has not changed during the past few decades."

Moreover, after analyzing the combinations of these parameters, the approval success rates of drugs that corresponded to the following categories-a stimulant in drug action or an enzyme in drug target and biologics in drug modality-were high (34.1% and 31.3%, respectively)

My understanding is SDC-1801 is the later of the two categories.

https://pubmed.ncbi.nlm.nih.gov/33831276/

This might be a decent read for those who are questioning the time things take and the costs involved. Hopefully it will highlight what little old Sareum has actually achieved so far.

"Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12–15 years and cost in excess of $1 billion."

Target Identification:

"Drugs fail in the clinic for two main reasons; the first is that they do not work and the second is that they are not safe. As such, one of the most important steps in developing a new drug is target identification and validation."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058157/

PCS- very well scripted

Warty: It’s pretty clear in your own post “ the CRT Pioneer Fund, has today licensed exclusive and worldwide rights for the Chk1 inhibitor ”
Who does it say has licensed the inhibitor??????
It’s an agreement and there are only 2 legally bound parties. SAR have a financial benefit under the licence but they are not part of the agreement. They are a third party and it isn’t that unusually in the IP world. A patent holder may license a product to another party who then may enter into a distribution agreement with a corporate group. Same situation.

Yes, I believe he said at 10.21
“We can’t divulge anything that GSK haven’t put into the public domain”
Certainly suggest they know something of interest

Afternoon Krone,

“So I would look out for the CHK1 at our 3Q update. ”
I maybe reading into something that’s not there…. However, that sentence “I would look out for the CHK1” is suggesting there is going to be a chk1 in the Q3 update ????

Utah- that’s a very interesting question. They may well say that not long ago the sp was 0.25p and rose to 9.5p or to make it easy for you, if you invested £10k you could have sold out the same investment for £380k. Now Utah, based on your suggestion the BoD have no business acumen, one would assume you have far more. So surely as a LTH this is what you did? Can you ask anymore from the BOD? Just a thought.

Potnak. Very well spotted!

Evening HBD, I think you’re probably spot on there
“Our database has hundreds of patients with inflammatory conditions ranging from skin to rheumatological diseases.”

Well found

Colbatblue, my answer would be a placing. However that’s not necessarily always a bad thing is it? I would happy to accept a 25% dilution if the result was funding P2. If successful this would result in many multiple increase in the SP.